@

scioCD - Cell Surface Marker and Cytokine Profiling

Immune response profiling

Cellular composition and signalling

CD-Marker Expression Profiles

 

 

 

Our scioCD profiling service covers 349 different proteins :

    • up to 141 unique CD-marker molecules
  • up to 119 Cytokines/Chemokines
  • other relevant proteins such as various HLAs and p53


All these proteins can be analysed in parallel within a single experiment from minute sample amounts. Thereby, scioCD antibody array analysis service is ideally suited to investigate cell composition of samples and signalling in a highly parallel, fast and robust fashion. In addition, protein distribution in blood samples (plasma / serum) can be analysed efficiently.

scioCD is a complete sample-to-result service for a variety of different sample types. The respective protocols were developed over a period of 15 years and are optimised towards highest possible sensitivity combined with high reproducibility (coefficients of variation below 10%).

 

 

      Analysis
Service       Sample
Types       Contact
us

 

  

Applications

  • profiling of cell differentiation status
  • stem cell differentiation 
  • investigate soluble CD-molecules for e.g. allograft rejection
  • inflammatory response profiling
  • immuno-oncology profiling of check-point inhibitor targets
  • characterisation of tissue-isolated primary cells
  • immune-cell surface marker profiling on
    • various B-cells 
    • stimulated T-cells
    • patient derived T-cells
    • patient derived dendritic cells
  • oncology profiling for new biomarkers e.g. Leukemia
  • tumor micro-environment profiling
  • profile response to stimuli of cell lines
  • evaluate protein expression changes in silencing/overexpression  experiments
  

Advantages

  • high content: up to 349 proteins are analysed
  • broad coverage and parallel analysis of
    • CD molecules 
    • cytokines and chemokines
    • other relevant molecules (HLAs, p53)
  • minimal sample requirements
  • native matrixes ( non-fractionated / non-depleted )
  • sensitivity as ELISA or better
  • fully immuno-based assay
  • reliable dual-colour study design
  • high reproducibility, CV < 10%
  • most proteins are covered redundantly by two or more antibodies
  • each antibody is presented in four replicates

 

Which sample types can be analysed ?

Within our scioCD analysis service the following samples can be analysed:

  • plasma  or serum
  • fresh frozen tissue samples
  • cellular samples
  • cell culture samples
  • cerebrospinal fluid (CSF)
  • additional sample types on request

  

Sample-to-result service

Within the analysis service, we will not only carry out the microarray experiments but also support you with a suggestion for an appropriate microarray study design as well as with the sample selection process in order to address your scientific question in the optimal way. Within 3-4 weeks after receipt of your samples you will receive a customised study report including a statistical analysis.

Our analysis service includes:

  • definition of an appropriate study design
  • sample preparation
  • protein extraction
  • protein concentration measurements
  • protein quality control
  • sample labelling
  • sample purification
  • incubation of the samples on antibody microarrays
  • microarray scanning
  • raw data acquisition
  • data normalisation
  • data analysis including cluster analysis
  • statistical testing for differentially abundant proteins
  • comprehensive study report


 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status
Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure.  This combination provides a comprehensive overview of signaling events and pathway activity…
Read more
scioUbi: protein profiling and ubiquitination status

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level
Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling
Immune response profiling Cellular composition and signalling CD-Marker Expression Profiles       Our scioCD profiling service covers 349 different proteins : up to 141 unique CD-marker molecules up to 119…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling
scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023). 
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.
New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
Article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

Testimonials

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

BACK_TO_TOP